Warning Letter to LPG USA

August 20, 2006

Department of Health and Human Services' logo Department of Health and Human Services

Public Health Service
Food and Drug Administration
Center for Devices and Radiological Health


2098 Gaither Rd
Rockville, MD 20850

June 5, 1997

Nathalie Guitay, President
3101 N Federal Hwy #301
Fort Lauderdale, FL 33306

Ref. No. K954399

Dear Ms Guitay:

The Food and Drug Administration (FDA) has reviewed a promotional journal distributed by LPG USA, Inc. (LPG) titled, ENDERMOLOGIE which is directed to plastic surgeons and that discusses the use of the ES1 davice. The ES1 in manufactured by WLPG Systems, Valence, France, distributed by LPG, and is a device within the meaning of section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act).

On June 4, 1997 [redacted] to us that the ES1 device ia identical to the “CM6G device which LPG markets as a therapeutic massager. Our records indicate LPG distributes the CM6G as a therapeutic massager that was found to be exempt from the 510(k) premarket notification requirements on September 27, 1996, based on information that LPG provided to FDA’s Office of Device Evaluation. As long as your claims are limited to those specified in the regulation under 21 CFR 890.5660 i.e., intended for medical purposes, such as to relieve minor muscle aches and pains, your device remains exempt. However, LPG’s brochure and other promotional materials reviewed by our office promote the ES1 as a “non-surgical alternative to liposuction,” and as a device “which combines a rolling technique with variable and mobile suctioning.” The device is described as one which was made up of two elements: a technical console and a treatment head “used to perform the aspirated hypodermal mobilization.” Additionally, your brochure makes tha following medical claims for the Ml:

  • “acts on tho hypodermal layer and can be used before, during, and after liposuction;”
  • claims that the ES1 is indicated in post and pre-operative cases, including cosmetic surgery, treatment of cellulite, the enhancement of liposuction “through aiding the absorption of hematomas, balancing the condition of the tissues of the lower limbs which sometimes react differently, pre-operatively softening the fibrous layer of the hypodermic to facilitate the passage of the canula and post-operatively treating persistent fibrosis”
  • claims that Endermologie using the ES1 unblocks circulation by increasing blood and oxygen flow in suffocated cellulite tissue and by accelerating the drainage of stagnant toxic wastes] helps to reduce the appearance of cellulite;
  • claims that the ES1 reduces fibrosis, breaks down fats, “disorganizes fat clusters and helps adipocytes evacuate the fat storage,”
  • stimulates tissues so that their natural elasticity is restored; claims that the device can increase skin tone and reduce dimpling;
  • claims that the device can be used as an alternative to surgery and that it reduces recovery time.

Similar claims are also found on your joint website with the Fountain of Youth Institute at the Internet home page address: www.afountainofyouth.com. The above listing is a representative example of medical claims made and is not meant to be all-inclusive. LPG, because of its promotional activities, has established the ES1 as a medical device subject to the 510(k) premarket notification filing requirements and removes the exemption.

Marketing the CM6G Therapeutic Massager as the ES1 device with the above claims causes these devices to be adulterated within the meaning of section 501(f)(1)(B) of the Act in that they are Class III devices under section 513(f), and do not have approved applications for premarket approval (PMA) in effect pursuant to section 515(a), or approved applications for investigational device exemptions (IDE) under section 520(g).

The CM6G Therapeutic Maasager as the ES1 device is also misbranded within the meaning of section 502(o) of the Act, in that notices or other information respecting the modification in the intended use(s) of the devices was not provided to FDA as required by 21 CFR 807.81(a)(3)(ii) and the devices were not found to be substantially equivalent to a predicate device.

This letter is not intended to be an all-inclusive list of deficiencies associated with your CM6G Therapeutic Massager/ESl device. It is your responsibility to ensure adherence to each requirement of the Act and Federal regulations. The specific violations noted in this letter may represent practices used in other promotion or advertisinq materials used by your firm. You are responsible for investigating and reviewing these materials to ensure compliance with applicable regulations.

You should take prompt action to correct these violations. Failure to promptly correct these deviations may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and/or civil penalties.

Please notify this office, in writing, within 15 working days of receipt of this letter, outlining the specific steps you have taken to correct the cited violation. Your response should also include all steps being taken to address misleading information currently in the market place and actions to prevent similar violation in the future. If corrective action cannot be completed within 15 working days, state the reason for the delay and the time within which the corrections will be completed. Your response should be sent to Mr Steven E. Budabin, Consumer Safety Officer, Promotion and Advertising Policy Staff (HFZ-302), Office of Compliance, Center for Devices and Radiological Health, 2098 Gaither Rd, Rockville, MD 208S0.

A copy of this letter is being sent to FDA’s Florida District Office. Please send a copy of your response to the District Director, Food and Drug Administration, Florida District Office (HFR-SE240), 7200 Lake Ellenor Dr #120, Orlando, FL 32809.

Sincerely yours,
Byron Tart for
Liliian J. Gill
Director, Office of Compliance

This page was posted on August 20, 2006.